Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (357)	11/4/1998 11:51:00 AM
From: Mike McFarland	Respond to of 4474

re Ariad patents; In light of today's INCY news release which states Incyte Issued First EST Gene Patent... This patent, which issued on October 6, 1998, is the first of Incyte's EST patents to issue and covers expressed sequence tags (ESTs) which encode 44 novel protein kinases... Incyte has generated a broad intellectual property portfolio that includes 92 issued US patents and US patent applications filed that cover over 1,500 full-length genes and over 1.2 million EST sequences. ... biz.yahoo.com Ariad said in a press release back in August that ARIA - news), has licensed from Pangea state-of-the-art computational tools that allow more rapid and accurate clustering and alignment of Expressed Sequence Tags (ESTs) within large databases.... ''With these tools we can optimally exploit sequence information and leverage our investment in proprietary EST databases.'' biz.yahoo.com I wonder if Ariad has any gene patents yet? -MM